Press release
Lupus Nephritis Market Report Examines Leading Companies And Growth Opportunities
Lupus Nephritis Market
Lupus Nephritis Market Size Projections Through 2030
The lupus nephritis market is anticipated to experience significant expansion, reaching a valuation of $2.98 billion by 2030. This represents a compound annual growth rate (CAGR) of 7.4% over the forecast period. Factors contributing to this growth include heightened investment in biologic drug development, greater emphasis on early diagnosis to prevent kidney failure, increasing use of combination therapy regimens, growth of specialty nephrology clinics, and rising healthcare expenditures on managing autoimmune diseases. Prominent trends expected to influence the market involve enhanced disease monitoring, wider adoption of immunosuppressive and biologic treatments, personalized therapeutic strategies, expanded long-term management programs, and growing awareness about autoimmune-related kidney complications.
The lupus nephritis market size has grown strongly in recent years. It will grow from $2.08 billion in 2025 to $2.24 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing prevalence of systemic lupus erythematosus, improved kidney biopsy and diagnostic practices, widespread use of corticosteroids in treatment, growing hospital-based nephrology care, increased awareness of autoimmune kidney diseases.
Download a free sample of the lupus nephritis market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22044&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Key Players Leading the Lupus Nephritis Market Landscape
Several prominent organizations dominate the lupus nephritis sector, including F Hoffmann La Roche Ltd, Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca PLC, Pfizer Inc, Johnson and Johnson, Merck and Co Inc, Sanofi, AbbVie Inc, Bayer AG, Amgen Inc, UCB SA, Otsuka Pharmaceutical Co Ltd, Aurinia Pharmaceuticals Inc, RemeGen Co Ltd, Kezar Life Sciences, Equillium Inc, Kyverna Therapeutics Inc, and Biogen Inc.
In a notable development from March 2024, Lupus Therapeutics-an affiliate clinical research partner of the Lupus Research Alliance based in the US-joined forces with Artiva Biotherapeutics Inc. to advance a clinical trial for lupus nephritis. This collaboration focuses on a Phase 1 trial assessing Artiva's AlloNK therapy combined with anti-CD20 antibodies for patients suffering from active lupus nephritis, evaluating its safety and efficacy. Artiva Biotherapeutics is a US biotechnology firm specializing in treatments for this serious kidney condition.
Emerging Trends Shaping Lupus Nephritis Treatment Approaches
A key trend in the lupus nephritis market is the ongoing development of second-generation calcineurin inhibitors aimed at improving treatment effectiveness and long-term kidney health. These inhibitors function by modulating immune responses to reduce inflammation and prevent further renal damage.
For example, in September 2024, Aurinia Pharmaceuticals Inc., a Canadian biopharmaceutical company, announced that Japan's Ministry of Health, Labour, and Welfare granted approval for LUPKYNIS (voclosporin) to treat lupus nephritis. This authorization allows voclosporin to be used alongside mycophenolate mofetil (MMF), based on positive results from the AURORA Clinical Program demonstrating both safety and efficacy. This milestone expands treatment options in Japan, enhancing disease management and patient outcomes.
View the full lupus nephritis market report:
https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Detailed Segmentation and Market Share Analysis in Lupus Nephritis
The lupus nephritis market is segmented across several important categories:
1) Disease Stage: Class 1, Class 2, Class 3, Other Stages
2) Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs
3) Route of Administration: Oral, Parenteral, Other Routes
4) Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) End-User: Hospitals, Specialty Clinics, Other End-Users
Further breakdown within stages includes:
- Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis
- Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition
- Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation
- Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)
This comprehensive segmentation enables a nuanced understanding of market dynamics and supports targeted development and marketing strategies within the lupus nephritis field.
The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lupus Nephritis Market Report Examines Leading Companies And Growth Opportunities here
News-ID: 4609642 • Views: …
More Releases from The Business Research Company
Major Depressive Disorder Market Trends Support A 3.9% CAGR Outlook Through The …
The major depressive disorder market is poised for steady advancement in the coming years, driven by various evolving factors in mental health care. Understanding the market's current valuation, innovation trends, leading players, and segment breakdown offers valuable insight into its future trajectory.
Projected Market Valuation and Growth Outlook for the Major Depressive Disorder Market
The major depressive disorder market is forecasted to expand to $7.49 billion by 2030, growing at…
Macular Degeneration Treatment Market Report Examines Industry Trends, Growth Dr …
The market for macular degeneration treatments is poised for significant expansion as new therapies and technologies emerge. With an aging global population and increasing healthcare investments, this sector is capturing the attention of researchers, companies, and patients alike. Let's explore the current market value, key players, emerging trends, and the major segments that define this growing field.
Projected Market Value and Growth Trajectory of the Macular Degeneration Treatment Market
The…
Lung Cancer Liquid Biopsy Market Outlook Highlights Strategic Opportunities Acro …
The lung cancer liquid biopsy market is set to experience significant expansion in the coming years, driven by advancements in diagnostic technology and increasing demand for personalized oncology approaches. As the healthcare sector evolves, this market is becoming a crucial component in early cancer detection and treatment monitoring. The following sections offer a detailed overview of its size, key players, emerging trends, and segmentation.
Projected Growth Outlook of the Lung Cancer…
Lower Respiratory Tract Therapeutics Market Study Explores Industry Growth Towar …
A growing global focus on respiratory health is driving significant advancements in treatments for lower respiratory tract conditions. With increasing awareness and the expansion of healthcare services worldwide, the market for lower respiratory tract therapeutics is poised for substantial growth. Below, we explore the market size projections, key players, emerging trends, and segment breakdowns shaping this important healthcare sector.
Anticipated Market Expansion of the Lower Respiratory Tract Therapeutics Market
The…
More Releases for Lupus
Lupus Nephritis Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the …
DelveInsight's Lupus Nephritis Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Lupus Nephritis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Lupus Nephritis pipeline domain.
Key takeaways from the Lupus Nephritis Clinical Trial Landscape Report
• DelveInsight's Lupus Nephritis pipeline report depicts a robust space with 25+ active players working to develop 40+…
Cutaneous Lupus Erythematosus (CLE) Market
Introduction
Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disorder, often associated with systemic lupus erythematosus (SLE), that presents as inflammation, rashes, and photosensitivity. While CLE is rarely fatal, it significantly affects patients' physical and emotional well-being, often leading to scarring, disfigurement, and social stigma.
Over the past decade, the market for CLE therapies has gained global importance as research into autoimmunity has accelerated and biologic therapies have transformed dermatology. Rising…
Cutaneous Lupus Erythematosus (CLE) Market
Market Overview:
The Global Cutaneous Lupus Erythematosus (CLE) Market is forecasted to achieve a High CAGR during the period 2023-2030. CLE encompasses a spectrum of dermatological symptoms that may precede or accompany systemic lupus erythematosus (SLE), an autoimmune condition impacting multiple organs. Timely diagnosis and treatment of CLE can prevent the onset of severe systemic symptoms.
Market Dynamics:
Drivers:
Rise in Clinical Studies: Technological advancements leading to faster and accurate diagnosis have spurred additional…
Lupus Nephritis Treatment Market 2030
Global Lupus Nephritis Treatment market is expected to be worth roughly USD 8,048 million by 2030, growing at a CAGR of 7.3% during the forthcoming period of 2022-2030, according to Ameco Research
Lupus nephritis is one of the most rapidly spreading diseases over the globe. The increasing frequency of lupus nephritis and consumer awareness has fuelled the worldwide lupus nephritis treatment market. Another crucial factor driving the pace of growth of…
Lupus Erythematosus Market -API Insights, 2017
Summary
Orbis Research Present “Lupus Erythematosus-API Insights, 2017”
Description
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage…
Global Systemic Lupus Erythematosus and Lupus Nephritis Market to Display 10.6% …
"The Report PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz has announced the addition of a new report, titled “PharmaPoint: Systemic Lupus Erythematosus And Lupus Nephritis - Global Drug Forecast And Market Analysis To 2025,” to its expanding repository of research reports. The market…
